



Atrys agrees to sell ASPY to Grupo Echevarne for €145 million and refocuses its strategy on areas with greater growth potential

The transaction, subject to the relevant regulatory approvals and approval by the General Shareholders' Meeting, will reduce the leverage ratio (Net Financial Debt/Adjusted EBITDA) from 3.8x to 1.1x and lower annual financial expenses by around €13 million.

Madrid, 4 November 2025. Atrys Health has signed a share purchase agreement to transfer 100% of **Aspy Global Services S.A.U. (ASPY)** to **Grupo Echevarne, S.L.** for **€145 million**. The agreement also provides for **contingent consideration** of up to **€5 million** if the buyer transfers the asset to a third party within **one year** after closing for an amount **higher** than the agreed price.

Completion of the transaction is subject to authorisation from the relevant **regulatory authorities** and **approval by Atrys' General Shareholders' Meeting**, which will be called in the coming days. Closing is **expected in the first quarter of 2026**.

The divestment of the prevention business will allow Atrys to **concentrate resources** on its **core precision medical diagnosis and treatment businesses**, strengthen its **financial position**, and **accelerate organic growth** by focusing on business areas where it holds **leadership positions** and **greater return potential**.

The **proceeds** obtained will be used to **reduce the Group's financial debt**, targeting a **Net Financial Debt/Adjusted EBITDA ratio** of around **1.1x** (from **3.8x**) and **annual savings** in financial expenses of around **€13 million**.

Excluding the prevention area (ASPY) from the Atrys Group perimeter, **pro forma LTM Revenue** (from October 2024 to September 2025) will amount to **€142.5 million** and the Group's **Adjusted LTM EBITDA** to **€28.0 million**. **Pro forma LTM organic revenue growth** will increase from the current **+8.2%** to **+13.4%**.

Marian Isach, Chief Executive Officer of Atrys, stated: "This transaction **strengthens our balance sheet** and enables us to focus on the business areas where we have a **clear competitive edge** and **strong growth traction**. With **lower financing costs** and a **leaner structure**, we will accelerate **investment and innovation** while reinforcing our **international expansion**."

"**ASPY** has been **key** to the Group's development and we will support an **orderly transition**. This divestment opens a **new stage** for Atrys, **more focused** and with a **better growth profile**," added Isach.

About Atrys

Atrys is a global **healthtech** company that provides medical services in **prevention, diagnosis, and precision medical treatment** using innovative technologies. It is a leader in **telemedicine, oncology treatment, and occupational risk prevention**. Atrys has a team of **over 2,000 professionals**, operates in **six countries** across **Europe and Latin America**, and is the **only listed company** in the health technology sector in Spain. The company structures its activity around two main business areas: **precision medicine** and **preventive medicine**. The precision medicine area includes diagnostic activities —**telemedicine, nuclear medicine, anatomical pathology and molecular pathology**— and **oncology treatment**—**medical oncology and advanced radiotherapy**—; while the preventive medicine area focuses on **prevention and health promotion**, serving **over one million people** through **more than 200 ASPY branches** throughout Spain.



Media contacts

Diana Barriga
Atrys
dbarriga@atryshealth.com
+34 649 042 525

Marta Estarellas
Roman
m.estarellas@romanrm.com
+34 663 027 941